Keywords: Australia, TGA, Sanofi Pasteur, Panvax, H1N1, influenza, Side effects
654 suspected adverse reactions to Panvax reported to Australia’s TGA in one month
Article | 24 November 2009
The Australian national immunization program with the H1N1 2009 influenza vaccine Panvax, made by French drug major Sanofi-Aventis’ Sanofi-Pasteur unit, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
